Literature DB >> 3027963

Novel nuclear antigens recognized by human sera in lymphocytes latently infected by Epstein-Barr virus.

D T Rowe, P J Farrell, G Miller.   

Abstract

We have used three latently infected cell lines, X50-7, JC-5, and Raji, to identify two new nuclear antigen complexes by Western immunoblotting with human anti-EBNA (Epstein-Barr Virus Nuclear Antigen) sera. One antigen complex, termed EBNA III, is composed of a group of high molecular weight proteins between 130 and 160 kDa and the other antigen complex, termed EBNA IV, is a size-related group of polypeptides between 28 and 62 kDa. Both the EBNA III and EBNA IV groups of proteins display variation in size among the different strains of EBV. Cell fractionation of X50-7, JC-5, Raji, and C16, a cell clone of P3HR1, showed that both new antigen complexes were completely recovered from the nuclei of latently infected lymphocytes as were previously described EBNA I and II. Because these new antigens are only detected by anti-EBNA sera in EBV infected cells, it seems likely that they may be encoded by the viral genome and play some role in the immortalization of lymphocytes by the virus.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3027963     DOI: 10.1016/0042-6822(87)90446-6

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  30 in total

1.  CD4+ T-cell effectors inhibit Epstein-Barr virus-induced B-cell proliferation.

Authors:  S Nikiforow; K Bottomly; G Miller
Journal:  J Virol       Date:  2001-04       Impact factor: 5.103

2.  The Epstein-Barr virus (EBV) nuclear antigen 1 BamHI F promoter is activated on entry of EBV-transformed B cells into the lytic cycle.

Authors:  A L Lear; M Rowe; M G Kurilla; S Lee; S Henderson; E Kieff; A B Rickinson
Journal:  J Virol       Date:  1992-12       Impact factor: 5.103

3.  Monoclonal and polyclonal antibodies against Epstein-Barr virus nuclear antigen 5 (EBNA-5) detect multiple protein species in Burkitt's lymphoma and lymphoblastoid cell lines.

Authors:  J Finke; M Rowe; B Kallin; I Ernberg; A Rosén; J Dillner; G Klein
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

4.  Different patterns of Epstein-Barr virus gene expression and of cytotoxic T-cell recognition in B-cell lines infected with transforming (B95.8) or nontransforming (P3HR1) virus strains.

Authors:  R J Murray; L S Young; A Calender; C D Gregory; M Rowe; G M Lenoir; A B Rickinson
Journal:  J Virol       Date:  1988-03       Impact factor: 5.103

5.  Expression of the Epstein-Barr virus BamHI A fragment in nasopharyngeal carcinoma: evidence for a viral protein expressed in vivo.

Authors:  K J Gilligan; P Rajadurai; J C Lin; P Busson; M Abdel-Hamid; U Prasad; T Tursz; N Raab-Traub
Journal:  J Virol       Date:  1991-11       Impact factor: 5.103

6.  Expression of the BZLF1 latency-disrupting gene differs in standard and defective Epstein-Barr viruses.

Authors:  N Taylor; J Countryman; C Rooney; D Katz; G Miller
Journal:  J Virol       Date:  1989-04       Impact factor: 5.103

7.  Sequences of the Epstein-Barr Virus (EBV) large internal repeat form the center of a 16-kilobase-pair palindrome of EBV (P3HR-1) heterogeneous DNA.

Authors:  H B Jenson; P J Farrell; G Miller
Journal:  J Virol       Date:  1987-05       Impact factor: 5.103

8.  Genome rearrangements activate the Epstein-Barr virus gene whose product disrupts latency.

Authors:  C Rooney; N Taylor; J Countryman; H Jenson; J Kolman; G Miller
Journal:  Proc Natl Acad Sci U S A       Date:  1988-12       Impact factor: 11.205

9.  A promoter for the highly spliced EBNA family of RNAs of Epstein-Barr virus.

Authors:  M Bodescot; M Perricaudet; P J Farrell
Journal:  J Virol       Date:  1987-11       Impact factor: 5.103

10.  Polymorphic proteins encoded within BZLF1 of defective and standard Epstein-Barr viruses disrupt latency.

Authors:  J Countryman; H Jenson; R Seibl; H Wolf; G Miller
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.